Boehringer Snaps Up T3 Amid Broader Immuno-Oncology Push

 
• By Alaric DeArment

The German drug maker is spending CHF450m to acquire T3, which is focused on developing live bacteria to treat cancers.

Boehringer Ingelheim said it would spend up to CHF450m to acquire T3 Pharma • Source: Shutterstock

More from Deals

More from Business